Sign up
Pharma Capital

Immuron receives US patent on drug composition to treat Clostridium difficile

Clostridium difficile remains a major medical problem, causing an estimated economic burden of more than US$10 billion globally with 28,000 deaths per year in the US alone.
Immuron, a biotechnology company based in Melbourne, changed its name from Anadis in 2008

Immuron Limited (ASX:IMC) has received a patent by the United States Patent and Trademark Office (USPTO) for a method to treat Clostridium difficile (CD) infections.

Entitled ‘Methods and compositions for the treatment and prophylaxis of Clostridium difficile associated disease’, the patent describes a targeted drug composition including an enriched, hyperimmune polyclonal antibody preparation of bovine colostrum for use in treating CD, a bacteria that causes life threatening diarrhea.

The company’s drug candidate IMM-529 is in a phase 1/2a clinical trial in CD patients.

Problem is prevalent in “hospitals long-term in-patient care facilities”

Immuron chief executive officer Gary S Jacob said: “The claims of this new US patent provide broad coverage of the application of our proprietary technology to the treatment of CD infection.

“CDI remains a major medical problem causing an estimated annual economic burden of more than US$10 billion globally.

“The problem is especially acute in hospitals and in long-term in-patient care facilities and moreover the problem is compounded by the high rate of recurrence in patients treated with front line antibiotics.

“Immuron’s drug candidate IMM-529 is not antibiotic, it is comprised of a hyperimmune polyclonal antibody colostrum agent that is capable of binding and inactivating not only the CD toxin B but also spore antigens and vegetative cell antigens.”

Australian site identification process complete

The company’s phase 1/2a clinical trial of IMM-529 in patients with CD, which is being conducted in two clinics in Israel, has not met the anticipated patient enrolment.  

Immuron has addressed the issue by making changes to the enrolment protocol.

A feasibility and Australian site identification process is now complete, and the company expects to have Australian clinical sites open for recruitment of patients shortly.

Register here to be notified of future IMC Company articles
View full IMC profile View Profile
View All

Related Articles

Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.